FibroGen (FGEN)
(Delayed Data from NSDQ)
$0.84 USD
+0.03 (3.70%)
Updated Jul 9, 2024 04:00 PM ET
After-Market: $0.85 +0.01 (1.30%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
FGEN 0.84 +0.03(3.70%)
Will FGEN be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for FGEN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for FGEN
Zoetis (ZTS) Beats Q1 Earnings and Revenue Estimates
Vertex (VRTX), TreeFrog Sign Deal for Diabetes Cell Therapies
FGEN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why You Should Add Immunovant (IMVT) to Your Portfolio
Vertex (VRTX) Begins Rolling NDA Filing for Acute Pain Drug
Bio-Path (BPTH) Rises on Upbeat Updates From Blood Cancer Study
Other News for FGEN
FibroGen files for $300M mixed shelf offering
FibroGen files $300M mixed securities shelf
Goldman Sachs Sticks to Its Sell Rating for FibroGen (FGEN)
FibroGen to Host Part II of Virtual KOL Investor Event Series to Review FG-3246 Development Program in Metastatic Castration-Resistant Prostate Cancer on June 26, 2024
Pancreatic Cancer on the Rise: How Biotech Firms are Developing Groundbreaking Treatments